AF solution
Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
We are utilizing advanced organoid technology to revolutionize gastrointestinal (GI) tract disease research.
Our organoids, derived from human gastrointestinal tissues, provide a precise and dynamic model for studying a wide range of GI diseases, from inflammatory bowel disease (IBD) to gastric cancer.
Organoids offer a three-dimensional, patient-derived model that accurately mirrors the cellular and molecular aspects of human GI tissues, allowing for more relevant studies of disease mechanisms and drug responses.
With our organoid platforms, researchers can quickly screen potential therapeutic agents, significantly accelerating the discovery and development of new treatments for GI diseases.
Our organoids enable personalized drug response testing, providing valuable insights into which treatments are most effective for specific patients based on their unique genetic makeup.
Organoids reduce the need for animal testing, offering a more ethical and accurate approach to predicting human responses before clinical trials.
Join Lambda AF Solutions as we lead the way in transforming GI tract disease management through innovative organoid research. Together, we can develop targeted, effective, and safer therapies to improve patient outcomes.
We are utilizing organoid technology to transform the study of gland diseases, such as xerostomia and Sjogren’s Syndrome.
Our advanced organoid models, derived from human glandular tissues, offer a groundbreaking platform for understanding complex glandular functions and pathologies.
Organoids provide a three-dimensional model that replicates the architecture and function of human glands, offering a more accurate context for studying gland diseases.
With our organoids, researchers can directly test the efficacy and safety of new treatments on gland-specific diseases, accelerating the path from discovery to clinical trials.
Leveraging organoids derived from patient-specific cells, we can test individual responses to treatments, tailoring therapies to better suit each patient’s unique condition.
Organoids allow for detailed studies of disease progression and response to treatment, providing valuable insights that are predictive of outcomes in clinical settings.
Join us at Lambda AF Solutions as we pave the way for breakthroughs in gland disease research and treatment. Our use of organoid technology is setting new standards in the field, offering more effective, safer, and personalized treatment options for patients.
We are pioneering the use of organoid technology to revolutionize research into metabolic diseases.
Our advanced organoids, including liver and kidney models with the potential to incorporate additional organ types provide a comprehensive platform for studying complex metabolic disorders.
Our organoids simulate various human organs, not limited to liver and kidney. This flexibility allows us to explore a wide range of metabolic diseases in organs such as the pancreas, thyroid, and beyond.
Utilize our organoids for rapid and efficient screening of potential therapeutic agents, accelerating the development of new treatments for metabolic disorders.
Leverage our organoids to tailor treatments according to individual genetic profiles, enhancing the effectiveness and reducing side effects of metabolic disease therapies.
With organoids, we minimize the reliance on animal testing and offer more relevant human-based models, improving the safety and ethical standards of our research.
Join us as we set new standards in the treatment and understanding of metabolic diseases. Our use of diverse organoid models marks a significant advancement in creating more effective and personalized therapies.
We lead the way in brain and central nervous system (CNS) disease research using innovative zebrafish and organoid models.
These models, along with potential future expansions into other advanced research platforms, offer unparalleled opportunities for studying complex neurological conditions.
Zebrafish and organoids provide dynamic systems to model brain and CNS diseases, allowing detailed studies of neurodevelopment and neurodegeneration in environments that closely mimic human biology.
Leverage these models for rapid screening of potential neurological drugs and therapies, facilitating faster development cycles and reducing time to clinical trials.
Both zebrafish and organoids are excellent for genetic manipulation and cellular analysis, enabling researchers to understand the genetic underpinnings of brain disorders and test genetic-based interventions.
These models offer ethical alternatives to traditional animal models, reducing reliance on higher-order vertebrates and aligning with modern ethical research standards.
Partner with us to explore and tackle brain and CNS disorders. Our commitment to integrating advanced models like zebrafish and organoids—and potentially others in the future—sets new benchmarks in neurological research.
We are advancing the field of respiratory and ENT (Ear, Nose, and Throat) diseases using our state-of-the-art respiratory organoids.
These organoids offer a dynamic and accurate model for studying a wide range of respiratory and ENT conditions, from chronic respiratory diseases to infections and cancers affecting these crucial areas.
Our respiratory organoids accurately replicate the cellular architecture of the human airway, providing an ideal platform for studying disease mechanisms, progression, and treatment responses.
These organoids enable the rapid screening of potential drugs and treatments, accelerating development cycles and allowing for earlier intervention strategies.
By using organoids derived from patient-specific cells, we can tailor treatments to individual responses, enhancing treatment efficacy and reducing potential side effects.
Respiratory organoids provide predictive data on how diseases will respond to treatments, helping to guide clinical decisions and improve patient outcomes.
Join us to set new standards in the treatment and understanding of respiratory and ENT diseases. Our innovative use of respiratory organoids is paving the way for breakthrough therapies that are more effective and less invasive.
@ 2024 . All rights reserved
@ 2024 . All rights reserved